UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 3.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 201,672 shares of the medical technology company’s stock after purchasing an additional 5,883 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.14% of Alphatec worth $1,121,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in ATEC. Van ECK Associates Corp raised its stake in Alphatec by 11.8% in the second quarter. Van ECK Associates Corp now owns 12,275 shares of the medical technology company’s stock valued at $128,000 after purchasing an additional 1,300 shares in the last quarter. Atria Investments Inc increased its holdings in shares of Alphatec by 8.0% in the 3rd quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock worth $109,000 after buying an additional 1,460 shares during the last quarter. Entropy Technologies LP increased its holdings in shares of Alphatec by 14.9% in the 3rd quarter. Entropy Technologies LP now owns 21,623 shares of the medical technology company’s stock worth $120,000 after buying an additional 2,800 shares during the last quarter. Wrapmanager Inc. raised its position in shares of Alphatec by 9.5% during the 3rd quarter. Wrapmanager Inc. now owns 38,399 shares of the medical technology company’s stock valued at $213,000 after buying an additional 3,325 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Alphatec by 15.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 27,243 shares of the medical technology company’s stock worth $285,000 after acquiring an additional 3,664 shares during the last quarter. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Alphatec Trading Down 7.4 %

Shares of ATEC stock opened at $8.82 on Thursday. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The business has a 50-day moving average of $8.14 and a 200 day moving average of $8.12. The stock has a market capitalization of $1.25 billion, a PE ratio of -6.89 and a beta of 1.38. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $17.34.

Wall Street Analysts Forecast Growth

ATEC has been the topic of a number of research analyst reports. Canaccord Genuity Group reissued a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research note on Friday, August 30th. Needham & Company LLC reiterated a “buy” rating and issued a $13.00 price objective on shares of Alphatec in a report on Thursday, October 31st. Lake Street Capital decreased their price objective on Alphatec from $32.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd. Barclays boosted their target price on Alphatec from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 19th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Alphatec in a research report on Thursday, October 31st. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $17.11.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.